Taiwan Liposome Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taiwan Liposome in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Taiwan Liposome stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLC, but not buy additional shares or sell existing shares.
View analyst ratings for Taiwan Liposome or view top-rated stocks.

Wall Street analysts have given Taiwan Liposome a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Taiwan Liposome wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Taiwan Liposome saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 3,100 shares, a drop of 59.2% from the August 15th total of 7,600 shares. Based on an average trading volume of 43,100 shares, the days-to-cover ratio is currently 0.1 days.
View Taiwan Liposome's Short Interest.

Taiwan Liposome is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Taiwan Liposome.

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) announced its quarterly earnings results on Thursday, August, 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.16. The firm earned $5.74 million during the quarter, compared to analyst estimates of $0.80 million. Taiwan Liposome had a negative net margin of 299.27% and a negative trailing twelve-month return on equity of 120.45%.
View Taiwan Liposome's earnings history.

Taiwan Liposome's stock was trading at $3.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TLC shares have increased by 88.3% and is now trading at $7.25.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 12-month target prices for Taiwan Liposome's stock. Their forecasts range from $7.50 to $7.50. On average, they expect Taiwan Liposome's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Taiwan Liposome or view top-rated stocks among Wall Street analysts.

Some companies that are related to Taiwan Liposome include Enanta Pharmaceuticals (ENTA), ImmunoGen (IMGN), ChemoCentryx (CCXI), RAPT Therapeutics (RAPT), Janux Therapeutics (JANX), Arcutis Biotherapeutics (ARQT), Repare Therapeutics (RPTX), Olema Pharmaceuticals (OLMA), MannKind (MNKD), Bicycle Therapeutics (BCYC), Northwest Biotherapeutics (NWBO), Precigen (PGEN), Axsome Therapeutics (AXSM), Aclaris Therapeutics (ACRS) and Innoviva (INVA).
View all of TLC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Taiwan Liposome investors own include Gilead Sciences (GILD), Pfizer (PFE), Wells Fargo & Company (WFC), Agnico Eagle Mines (AEM), Applied Genetic Technologies (AGTC), Celldex Therapeutics (CLDX), Seabridge Gold (SA), Trevena (TRVN), AbbVie (ABBV) and Advanced Micro Devices (AMD).

(TLC) raised $29 million in an initial public offering on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

Taiwan Liposome trades on the NASDAQ under the ticker symbol "TLC."

Taiwan Liposome's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.03%).

TLC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Shares of TLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TLC stock can currently be purchased for approximately $7.25.

Taiwan Liposome has a market capitalization of $305.08 million and generates $3.63 million in revenue each year. The company earns $-35,020,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

The official website for Taiwan Liposome is www.tlcbio.com.

Taiwan Liposome is headquartered at 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503.

Taiwan Liposome's mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company can be reached via phone at 886226557377 or via email at [email protected].